Completed PHASE1 INTERVENTIONAL 3-arm NCT01713608

A Dose-escalation Study to Investigate Safety and Toleration of OZ439

A Randomised, Placebo-controlled, Dose-escalation Study to Investigate Safety and Toleration of OZ439 OD for 3 Days to Healthy Male and Female Volunteers

Sponsor: Medicines for Malaria Venture

Conditions Malaria

Interventions OZ439

Updated 7 times since 2017 Last updated: Mar 12, 2015 Started: Nov 30, 2012 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01713608, this PHASE1 trial focuses on Malaria and remains completed. Sponsored by Medicines for Malaria Venture, it has been updated 7 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medicines for Malaria Venture

Data source: Medicines for Malaria Venture

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Croydon, United Kingdom